Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29139343 | 0.81 | ALDH1A1 (0.37) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL745826 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| Hydrogen Sulfide SCHEMBL17534845 | 0.79 | ALDH1A1 (0.45) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL10340551 | 0.78 | ALDH1A1 (0.43) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL6687766 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL1268139 | 0.74 | SMN1; SMN2 (0.52) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL44725 | 0.74 | ALDH1A1 (0.50) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL24599713 | 0.73 | EHMT2 (0.59) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL16132722 | 0.73 | EHMT2 (0.59) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 | |
| SCHEMBL5153054 | 0.73 | SMN1; SMN2 (0.39) | SMN1; SMN2HSD17B10HPGDEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804631-B1 | SURROBODY CONJUGATES | I2 PHARMACEUTICALS INC (US) | 2021-03-17 | — | — | EP | claimed |
| EP-2914630-B1 | NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2021-03-03 | — | — | EP | claimed |
| EP-2804631-A1 | SURROBODY COJUGATES | Sea Lane Biotechnologies,llc. (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013109994-A1 | SURROBODY COJUGATES | SEA LANE BIOTECHNOLOGIES, LLC (US) | 2013-07-25 | — | — | WO | claimed |
| EP-2032172-B1 | LEPTOMYCIN DERIVATIVES | SANOFI SA (FR) | 2012-06-06 | — | — | EP | claimed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | claimed |
| US-7514078-B2 | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | PIERRE FABRE MEDICAMENT (FR) | 2026-05-28 | — | — | US | disclosed |
| EP-3620473-B1 | NOVEL HETERODIMERIC PROTEINS | XENCOR INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748862-A2 | HETERODIMERIC PROTEINS | Xencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748856-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SELF-DRIVING CHIMERIC ANTIGEN RECEPTORS | Lentigen Technology, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026100671-A1 | ANTI-GPRC5A ANTIBODY AND USES THEREOF | リベロセラ株式会社 | 2026-05-15 | — | — | WO | disclosed |
| EP-4739396-A1 | HUMANIZED 40H3 ANTIBODY | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-0428534-B1 | COUPLING AGENTS AND STERICALLY HINDERED DISULFIDE LINKED CONJUGATES PREPARED THEREFROM | CETUS ONCOLOGY CORP (US) | 1995-03-29 | — | — | EP | disclosed |
| US-5208020-A | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0528527-A2 | Conjugates | ZENECA LIMITED (GB) | 1993-02-24 | — | — | EP | disclosed |
| US-5165923-A | Anticarcinogenic agents by elimination of cells using a toxin conjugate | IMPERIAL CANCER RESEARCH TECHNOLOGY (GB) | 1992-11-24 | — | — | US | disclosed |
| EP-0502101-A1 | COMPOSITIONS FOR THE TREATMENT OF HODGKIN'S DISEASE | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007941-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HODGKIN'S DISEASE | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991007437-A2 | IMPROVED CD-30 ANTIBODIES AND FRAGMENTS THEREOF | PARKER, DAVID, L. (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | IGF1R, CD44, MUC1 | SMN1; SMN2 120/4885HSD17B10 3539/4885HPGD 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.